Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 4/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3243114 | 0.89 | CYP1A2 (0.61) | CYP1A2MEN1KMT2AAPPHRH3 | |
| SCHEMBL1108639 | 0.84 | NPC1 (0.62) | CYP1A2MEN1KMT2AAPPRAB9A | |
| SCHEMBL12832443 | 0.84 | CYP2C19 (0.56) | CYP1A2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL13763363 | 0.82 | CYP1A2 (0.65) | CYP1A2APPHRH3ALDH1A1LMNA | |
| SCHEMBL27513658 | 0.82 | CYP1A2 (1.00) | CYP1A2APPHRH3ALDH1A1LMNA | |
| SCHEMBL6677526 | 0.82 | CYP1A2 (0.69) | CYP1A2APPHRH3ALDH1A1LMNA | |
| SCHEMBL13757443 | 0.81 | CYP1A2 (0.63) | CYP1A2MEN1KMT2AAPPHRH3 | |
| SCHEMBL12994650 | 0.80 | NPC1 (0.68) | CYP1A2APPHRH3ALDH1A1LMNA | |
| SCHEMBL11561635 | 0.80 | RAB9A (0.63) | MEN1KMT2AALDH1A1LMNATAAR1 | |
| SCHEMBL6645913 | 0.78 | MAPT (0.53) | KMT2AALDH1A1LMNARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658291-B1 | SUBSTITUTED 8-HETEROARYL XANTHINES | DOGWOOD PHARMACEUTICALS INC (US) | 2013-10-02 | — | — | EP | disclosed |
| US-8153628-B2 | Pyrazolyl substituted xanthines | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2012-04-10 | — | — | US | disclosed |
| US-8153628-B2 | Pyrazolyl substituted xanthines | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2012-04-10 | — | — | US | disclosed |
| EP-2295434-A2 | Substituted 8-heteroaryl xanthines | Adenosine Therapeutics, LLC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20100273780-A1 | SUBSTITUTED 8-HETEROARYL XANTHINES | PGXHEALTH, LLC (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273780-A1 | SUBSTITUTED 8-HETEROARYL XANTHINES | PGXHEALTH, LLC (US) | 2010-10-28 | — | — | US | disclosed |
| US-7732455-B2 | Substituted 8-heteroaryl xanthines | PGX HEALTH, LLC (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732455-B2 | Substituted 8-heteroaryl xanthines | PGX HEALTH, LLC (US) | 2010-06-08 | — | — | US | disclosed |
| US-20100120765-A1 | PYRAZOLYL SUBSTITUTED XANTHINES | PGXHEALTH, LLC (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120765-A1 | PYRAZOLYL SUBSTITUTED XANTHINES | PGXHEALTH, LLC (US) | 2010-05-13 | — | — | US | disclosed |
| US-7601723-B2 | Pyridyl substituted xanthines | PGX HEALTH, LLC (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601723-B2 | Pyridyl substituted xanthines | PGX HEALTH, LLC (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080200456-A1 | Substituted 8-Heteroaryl Xanthines | ALLERGAN SALES, LLC | 2008-08-21 | — | — | US | disclosed |
| US-20080200456-A1 | Substituted 8-Heteroaryl Xanthines | ALLERGAN SALES, LLC | 2008-08-21 | — | — | US | disclosed |
| US-7342006-B2 | Substituted 8-heteroaryl xanthines | ADENOSINE THERAPEUTICS, LLC (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342006-B2 | Substituted 8-heteroaryl xanthines | ADENOSINE THERAPEUTICS, LLC (US) | 2008-03-11 | — | — | US | disclosed |
| US-20070072843-A1 | For treating asthma and improving insulin sensitivity | ADENOSINE THERAPEUTICS, LLC | 2007-03-29 | — | — | US | disclosed |
| US-20070072843-A1 | For treating asthma and improving insulin sensitivity | ADENOSINE THERAPEUTICS, LLC | 2007-03-29 | — | — | US | disclosed |
| US-20070066631-A1 | Pyrazolyl substituted xanthines | ADENOSINE THERAPEUTICS, LLC | 2007-03-22 | — | — | US | disclosed |
| US-20070066631-A1 | Pyrazolyl substituted xanthines | ADENOSINE THERAPEUTICS, LLC | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120765-A1 | PYRAZOLYL SUBSTITUTED XANTHINES | ADORA2B, ADORA2A, ADORA3 | CYP1A2 276/4885MEN1 4200/4885KMT2A 3345/4885 |
| US-20070066631-A1 | Pyrazolyl substituted xanthines | ADORA2B, ADORA2A, ADORA3 | CYP1A2 276/4885MEN1 4200/4885KMT2A 3345/4885 |
| US-20080200456-A1 | Substituted 8-Heteroaryl Xanthines | ADORA2B, ADORA2A, ADORA3 | CYP1A2 203/4885MEN1 4332/4885KMT2A 1888/4885 |
| US-20100273780-A1 | SUBSTITUTED 8-HETEROARYL XANTHINES | ADORA2B, ADORA2A, ADORA3 | CYP1A2 203/4885MEN1 4332/4885KMT2A 1888/4885 |
| US-20070072843-A1 | For treating asthma and improving insulin sensitivity | ADORA2B, GPR119, ADORA2A | CYP1A2 805/4885MEN1 2954/4885KMT2A 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.